IART
Integra LifeSciences Holdings Corporation
Set alert
- YTD
- +2.66%
- 1 year
- +7.96%
- Open
- 12.74
- Prev close
- 12.83
- Mkt cap
- 991.60M
- Vol
- 1.04M
- Avg vol
- 948.94K
- EPS
- 0.17
- P/E
- 75.00
- Div yield
- 0.00%
More statistics
- Low
- 12.34
- High
- 12.85
- Forward P/E
- 5.29
- Beta
- 1.21
- Short ratio
- 8.11
- Inst. own
- 98.42%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Oct 21, 2026
- 50-d avg
- 15.76
- 200-d avg
- 14.09
- 1y target
- 18.00
Key statistics
- Market cap
- 1.04B
- Enterprise value
- 2.82B
- Trailing P/E
- 0.00
- Forward P/E
- 5.29
- PEG ratio
- 0.67
- Price / sales
- 0.63
- Price / book
- 0.99
- EPS (TTM)
- -0.09
- Beta
- 1.21
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -0.44%
- Revenue (TTM)
- 1.65B
- Revenue growth
- 0.80%
- Free cash flow
- 94.40M
- Total cash
- 274.08M
- Total debt
- 2.05B
- Return on equity
- -0.70%
- Shares outstanding
- 77.77M
- Short % of float
- 12.88%
- 50-day average
- 15.76
- 200-day average
- 14.09
Analyst view
Consensus: hold
- Target (low)
- 14.00
- Target (mean)
- 18.00
- Target (high)
- 27.00
- Strong buy1
- Buy2
- Hold7
- Sell0
- Strong sell2
Next earnings
Oct 21, 2026
Expected Oct 21, 2026. Consensus EPS estimate 0.55915.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 21, 2026 | Sep 30, 2026 | 0.557 | — | — | — |
| Jul 29, 2026 | Jun 30, 2026 | 0.4805 | 0.56 | +0.08 | +16.55% |
| May 5, 2026 | Mar 31, 2026 | 0.41 | 0.54 | +0.13 | +31.71% |
| Feb 26, 2026 | Dec 31, 2025 | 0.79 | 0.83 | +0.04 | +5.06% |
| Oct 30, 2025 | Sep 30, 2025 | 0.43 | 0.54 | +0.11 | +25.58% |
| Jul 31, 2025 | Jun 30, 2025 | 0.43 | 0.45 | +0.02 | +4.65% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 14, 2026 | Truist Securities | main | Hold | Hold |
| Oct 5, 2026 | Citigroup | main | Neutral | Neutral |
| Oct 5, 2026 | BMO Capital | main | Market Perform | Market Perform |
| Jul 30, 2026 | Wells Fargo | main | Equal-Weight | Equal-Weight |
| Jul 28, 2026 | UBS | init | — | Neutral |
| Jul 16, 2026 | Truist Securities | main | Hold | Hold |
About Integra LifeSciences Holdings Corporation
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Surgical and Tissue Technologies segments. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. It also offers after-market services; surgical headlamps and instrumentation; instrument patterns and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices. In addition, the company provides treatment of acute wounds, such as burns; chronic wounds, including diabetic foot ulcers; and surgical tissue repair applications, including hernia reinforcement, tendon protection, and peripheral nerve repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, and nerve and tendon repair products. Additionally, the company is involved in the ear, nose, and throat business that includes instrumentation, balloon technologies for sinus dilation and eustachian tube dilation, and surgical navigation systems. It offers its products directly through various salesforces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, the Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was formerly known as Integra LifeSciences Corp. and changed its name to Integra LifeSciences Holdings Corporation in June 1995. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- integralife.com
News
- Integra LifeSciences to Highlight Hands-On Education and Neurosurgery Innovation at CNS 2026 Annual Meeting
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holding Corporation - IART
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holding Corporation - IART
- UBS Maintains Neutral on Integra Lifesciences, Lowers Price Target to $14
- Truist Securities Maintains Hold on Integra Lifesciences, Lowers Price Target to $13
- Integra LifeSciences: Progress Remains Frustratingly Slow, But Valuation Is Getting Interesting
- Lost Money on Integra LifeSciences Holdings Corporation Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 21.2% Share Price Drop
- Lost Money on Integra LifeSciences Holdings Corporation Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 21.2% Share Price Drop
- Did You Lose Money on Integra LifeSciences Holdings Corporation Stock? The Law Offices of Howard G.
- Citigroup Maintains Neutral on Integra Lifesciences, Lowers Price Target to $14
Your note
Sign in to keep a note on IART — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BRADLEY KEITH | Director | Stock Award(Grant) | May 8, 2025 | 89,136 |
| CLAY SHAUNDRA | Director | Stock Award(Grant) | May 8, 2025 | 41,515 |
| DAVIS ROBERT T JR | Officer | Stock Award(Grant) | Mar 10, 2025 | 75,561 |
| ESSIG STUART PH.D. | Officer and Director | Stock Award(Grant) | May 8, 2025 | 1,785,270 |
| GRAVES JEFFREY A. | Director | Purchase | Nov 4, 2025 | 41,086 |
| HILL BARBARA BENTON | Director | Stock Award(Grant) | May 6, 2026 | 187,541 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 13.74% | 10,684,103 | 142.42M | Jun 29, 2026 |
| Rubric Capital Management LP | 9.97% | 7,753,934 | 103.36M | Jun 29, 2026 |
| Invesco Ltd. | 4.82% | 3,749,367 | 49.98M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 4.81% | 3,743,093 | 49.90M | Jun 29, 2026 |
| Morgan Stanley | 4.62% | 3,593,079 | 47.90M | Jun 29, 2026 |
| Fuller & Thaler Asset Management Inc. | 4.42% | 3,436,006 | 45.80M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 5.24% | 4,072,320 | 54.28M | Aug 30, 2026 |
| AIM Sector Funds (Invesco Sector Funds)-Invesco Small Cap Value Fund | 4.36% | 3,389,024 | 45.18M | Jul 30, 2026 |
| UNDISCOVERED MANAGERS Fd.S-Undiscovered Managers Behavioral Value Fd. | 3.63% | 2,822,343 | 37.62M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.71% | 2,108,295 | 28.10M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.26% | 1,754,199 | 23.38M | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 1.95% | 1,515,002 | 20.19M | Jun 29, 2026 |